Ophthotech Corporation - Company & Market Research Reports

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. Its principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration (AMD). The company is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD. Ophthotech Corporation was founded in 2007 and is headquartered in New York, New York.

From
From
From
From
Uveitis - Pipeline Review, H2 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 207 Pages
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 195 Pages
From
From
From
Retinal Degeneration - Pipeline Insight, 2018 - Product Thumbnail Image

Retinal Degeneration - Pipeline Insight, 2018

  • Drug Pipelines
  • 217 Pages
From
From
From
From
Geographic Atrophy - Pipeline Review, H2 2018 - Product Thumbnail Image

Geographic Atrophy - Pipeline Review, H2 2018

  • Drug Pipelines
  • 79 Pages
From
From
From
From
From
Loading Indicator
adroll